Taken together, our findings suggest that tau hyperphosphorylation might play a significant role in cardiac fibrosis in T2DM, and LiCl treatment can ameliorate tau-hyperphosphorylation-induced cardiac injury. The gene discussed is MAPT; the disease is type 2 diabetes mellitus.